Vivant Medical Announces Clinical Study Data on the Microwave Ablation of Renal Tumors
Vivant Medical Announces the Presentation of Clinical Study Data on the Microwave Ablation of Renal Tumors at the American Urological Association’s Annual Meeting
Mountain View, CA - May 18, 2005 - Vivant Medical, Inc. announced today that data from a clinical study using its VivaWave™ Microwave Ablation system will be presented at the American Urological Association (AUA) Annual Meeting, which will be held May 21 – 26, 2005 in San Antonio, Texas. In a May 24, 2005 session titled “Kidney and Ureteral Cancer: Evaluation & Treatment,” Dr. Peter E Clark, Assistant Professor, Department of Urology at the Wake Forest University Baptist Medical Center will present his abstract titled “Phase II prospective evaluation of a novel microwave ablation system for renal masses during radical nephrectomy.”
The study, a prospective phase II, institutional review board approved study of 10 patients with a solid, enhancing renal mass who underwent microwave ablation followed by radical nephrectomy either laparoscopically or through an open approach. After nephrectomy, the ablated lesion was examined by visual inspection, by histopathology (the study of diseased tissue and cell samples under a microscope) and NADH vital staining (a means of confirming cell death by testing cellular viability). In his presentation Dr. Clark concluded that “VivaWave can be utilized to generate reproducible large ablative lesions in solid renal neoplasms.”
Rod Young, Chief Executive Officer of Vivant Medical, said, “Vivant Medical determined early on the importance of clinical validation for the VivaWave Microwave Ablation System. We are pleased with the results from this first renal study in which VivaWave was used.”
Presentations reviewing results of clinical studies in which VivaWave was used in other organs such as liver and lung have been presented at prestigious conferences such as SIR, RSNA, and the AHPBA.
About Vivant Medical, Inc.
The VivaWave Microwave Ablation System is a novel and proprietary technology developed by Vivant Medical, Inc., Mountain View, California, USA. The VivaWave System has received FDA 510(k) clearance for the coagulation of soft tissue, and the system is in clinical usage at medical centers and university hospitals worldwide. The VivaWave System has not been granted the CE Mark and is not available for sale or supply in Europe. For more information about Vivant Medical, please visit the Vivant web site.
6/24/2005
|
|
